5
Views
1
CrossRef citations to date
0
Altmetric
Original Articles

Controversies in diagnosis and treatment of hepatitis C

Which patients benefit most from therapy?

, MD
Pages 201-212 | Published online: 30 Jun 2015

References

  • Fried MW, Hoofnagle JH. Therapy of hepatitis C. Semin Liver Dis 1995; 15(1): 82–91
  • Alter MJ. Epidemiology of hepatitis C in the West. Semin Liver Dis 1995; 15(1): 5–14
  • Schreiber GB, Busch MP, Kleinman SH, et al. The risk of transfusion-transmitted viral infections. N Engl J Med 1996; 334(26):1685–90
  • Vertical Transmission of Hepatitis C Virus Collaborative Study. Transmission of hepatitis C virus from mothers to infants. N Engl J Med 1994; 330(11):744–50
  • Lam JP, McOmish F, Burns SM, et al. Infrequent vertical transmission of hepatitis C virus. J Infect Dis 1993; 167(3):572–6
  • Brillanti S, Foli M, Gaiani S, et al. Persistent hepatitis C viraemia without liver disease. Lancet 1993; 341 (8843):464–5
  • Sentinel Counties Chronic non-A, non-B Hepatitis Study Team. The natural history of community-acquired hepatitis C in the United States. N Engl J Med 1992; 327(27):1899–905
  • Young KK, Resnick RM, Myers TW. Detection of hepatitis C virus RN A by a combined reverse transcription-polymerase chain reaction assay. J Clin Microbiol 1993; 31(4):882–6
  • Detmer J, Lagier R, Flynn J, et al. Accurate quantification of hepatitis C virus (HCV) RNA from all HCV genotypes by using branched-DNA technology. J Clin Microbiol 1996; 34(4):901–7
  • Parés A, Barrera JM, Caballería J, et al. Hepatitis C virus antibodies in chronic alcoholic patients: association with severity of liver injury. Hepatology 1990; 12(6): 1295–9
  • Lin R, Roach E, Zimmerman M, et al. Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates: results of the first multicentre Australian trial. Australia Hepatitis C Study Group. J Hepatol 1995; 23(5):487–96
  • Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology 1996; 24(4):778–89
  • Van Thiel DH, Caraceni P, Molloy PJ, et al. Chronic hepatitis C in patients with normal or near normal alanine aminotransferase levels: the role of interferon alpha 2b therapy. J Hepatol 1995; 23(5):503–8
  • Sharara Al, Hunt CM, Hamilton JD. Hepatitis C. Ann Intern Med 1996; 125(8): 658–68
  • HIV-Hepatitis Spanish Study Group. Efficacy and safety of alpha-interferon treatment for chronic hepatitis C in HIV- infected patients. J Infect 1995; 31(1):9–13
  • Schvarcz R, Yun ZB, Sonnerborg A, et al. Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone. J Med Virol 1995; 46(1):43–7
  • Braconier JH, Paulsen O, Engman K, et al. Combined alpha-interferon and ribavirin treatment in chronic hepatitis C: a pilot study. Scand J Infect Dis 1995; 27(4): 325–9
  • Andreone P, Cursaro C, Gramenzi A, et al. Alfa-interferon plus indomethacin combined therapy for non-responder patients with chronic hepatitis C. (Abstr) Hepatology 1993; 18(4 Pt 2):221A
  • Andreone P, Cursaro C, Gramenzi A, et al. Pilot study of a-interferon and ketoprofen combined therapy in non-responsive patients with chronic hepatitis C: an interim report. (Abstr) Gastroenterology 1994; 106(4 Pt 2):A85

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.